Takeda Arunbrig's first-line treatment of NSCLC is positive

, Takeda announced that its next-generation ALC inhibitor, Brigatinib, has shown good long-term results in Phase 3 clinical trials for patients with ALC-positive non-small cell lung cancer (NSCLC). For more than 2 years of follow-up, Alunbrig, a first-line therapy, reduced the risk of disease progression or death by 57% compared to the common generation of APK inhibitors. In patients with brain metastasis, Alunbrig was able to reduce the risk of disease progression or death by 76%.Globally, there are about 1.8 million new lung cancer patients each year, and NSCLC is the most common type of lung cancer. In NSCLC patients, 3-5% of patients carry ALK gene fusion is the main factor driving cancer development, ALK inhibitors are particularly effective for them.Alunbrig is a next-generation tyrosine kinase inhibitor (TKI) developed by Takeda and designed to target and inhibit APK fusion proteins. In April 2017, it received FDA accelerated approval to treat ALC-positive metastasis NSCLC patients. The disease continued to progress after these patients were treated with crizotinib.In a randomized multi-center Phase 3 clinical trial called ALTA-1L, 275 patients with ALC-positive late stage or metastasis NSCLC were treated with Alunbrig or crizotinib. The patient had not previously been treated with APK inhibitors. The results showed that, according to the researchers' assessment, the progress-free survival (PFS) in patients in the Alunbrig group was 29.4 months, compared with 9.2 months in the active control group. For patients with brain metastases, the PFS in the Alunbrig group was 24 months and the active control group was 5.6 months. Alunbrig also significantly improves the quality of life of patients.Dr Phil Rowlands, head of oncology treatment at Takeda, said: "We are proud of the progress we have made. The results of alTA-1L clinical trials have shown that Alunbrig can delay disease progressity by more than 2 years and significantly reduce the risk of disease progress in patients with brain metastasis tumors. We look forward to submitting this data to regulators around the world in an effort to benefit Alunbrig for ALC-positive NSCLC patients worldwide. " (
medicine Mingkangde
)